Serum Metabolomic Analysis of Coronary Heart Disease Patients with Stable Angina Pectoris Subtyped by Traditional Chinese Medicine Diagnostics Reveals Biomarkers Relevant to Personalized Treatments
| Autor: | Peili Wang, Marjolein Wildwater, Monique van der Voet, Na Guo, Xuan Tang, Mei Wang, Junying Wei, Hongjun Yang, Xiaofang Yang, Jiaying Yang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Inflammation Traditional Chinese medicine RM1-950 030204 cardiovascular system & hematology Bioinformatics Stable angina Angina traditional Chinese medicine subtypes 03 medical and health sciences 0302 clinical medicine Metabolomics angina pectoris medicine Pharmacology (medical) coronary heart disease vascular endothelial damage Original Research chemistry.chemical_classification Pharmacology business.industry Metabolism medicine.disease metabolomics Coronary heart disease 030104 developmental biology chemistry Therapeutics. Pharmacology medicine.symptom business Polyunsaturated fatty acid |
| Zdroj: | Frontiers in Pharmacology Frontiers in Pharmacology, Vol 12 (2021) |
| ISSN: | 1663-9812 |
| Popis: | To improve the treatment of patients with coronary heart disease (CHD), personalized treatments based on potential biomarkers could make a difference. To investigate if such potential biomarkers could be found for CHD inhomogeneous, we combined traditional Chinese medicine based diagnosis with untargeted and targeted metabolomics analyses. Shi and Xu patient subtype groups of CHD with angina pectoris were identified. Different metabolites including lipids, fatty acids and amino acids were further analyzed with targeted metabolomics and mapped to disease-related pathways. The long-chain unsaturated lipids ceramides metabolism, bile acid metabolism were differentially affected in the Xu subtype groups. While, Shi-subtype patients seemed to show inflammation, anomalous levels of bioactive phospholipids and antioxidant molecules. Furthermore, variations in the endothelial damage response and energy metabolism found based on ELISA analysis are the key divergence points between different CHD subtypes. The results showed Xu subtype patients might benefit from long-chain unsaturated lipids ceramides as therapeutic targets. Shi subtype patients might benefit more from levels of polyunsaturated fatty acid consumption and treatments that help in restoring energy balance. Metabolic differences can be essential for treatment protocols. Thus, patient group specific differences can serve as important information to refine current treatment approaches in a personalized manner. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|